ABUS · Arbutus Biopharma Corporation Common Stock
View on chartInsiders & Stakes
| Roivant Sciences Ltd. 10% Owner | ▼ Sell | Other | 38,847,462 Shares held | 10/18/2021 | View profile |
| Michael J. McElhaugh Chief Business Officer | ▲ Buy | Grant | 1,658,003 Shares held | 2/14/2025 | View profile |
| Michael J. Sofia Chief Scientific Officer | ▼ Sell | Open Market | 1,485,121 Shares held | 2/2/2024 | View profile |
| David C. Hastings Chief Financial Officer | ▲ Buy | Grant | 249,824 Shares held | 2/14/2025 | View profile |
| Collier William H. President and CEO | ▲ Buy | Grant | 216,500 Shares held | 2/1/2023 | View profile |
| Karen Sims Chief Medical Officer | ▲ Buy | Grant | 155,494 Shares held | 2/14/2025 | View profile |
| J. Christopher Naftzger General Counsel and CCO | ▲ Buy | Grant | 140,544 Shares held | 2/14/2025 | View profile |
| Howard Elizabeth EVP, GC, Compliance | ▲ Buy | Grant | 86,024 Shares held | 2/1/2023 | View profile |
| Tuan Nguyen Chief Financial Officer | ▲ Buy | Grant | 73,500 Shares held | 2/2/2026 | View profile |
| Keith S. Manchester Director | ▼ Sell | Open Market | 46,069 Shares held | 8/14/2024 | View profile |
| Lindsay Androski Director | ▲ Buy | Grant | 28,000 Shares held | 2/2/2026 | View profile |
Transaction History
| Tuan Nguyen | ▲ Buy | Grant | 73,500 | $0 | 2/2/2026 |
| Lindsay Androski | ▲ Buy | Grant | 28,000 | $0 | 2/2/2026 |
| J. Christopher Naftzger | ▲ Buy | Grant | 54,300 | $0 | 2/14/2025 |
| Michael J. McElhaugh | ▲ Buy | Grant | 177,000 | $0 | 2/14/2025 |
| David C. Hastings | ▲ Buy | Grant | 90,100 | $0 | 2/14/2025 |
| Karen Sims | ▲ Buy | Grant | 49,300 | $0 | 2/14/2025 |
| David C. Hastings | ▼ Sell | Open Market | 22,183 | $73K | 2/4/2025 |
| Karen Sims | ▼ Sell | Open Market | 19,348 | $64K | 2/4/2025 |
| Michael J. McElhaugh | ▼ Sell | Open Market | 23,790 | $78K | 2/4/2025 |
| J. Christopher Naftzger | ▼ Sell | Open Market | 11,333 | $37K | 2/4/2025 |
| Keith S. Manchester | ▲ Buy | Option Exercise | 54,915 | $31K | 8/14/2024 |
| Keith S. Manchester | ▼ Sell | Open Market | 8,846 | $33K | 8/14/2024 |
| David C. Hastings | ▼ Sell | Open Market | 9,593 | $22K | 2/2/2024 |
| Michael J. Sofia | ▼ Sell | Open Market | 9,982 | $23K | 2/2/2024 |
| Michael J. McElhaugh | ▼ Sell | Open Market | 10,164 | $24K | 2/2/2024 |
| Karen Sims | ▼ Sell | Open Market | 4,358 | $10K | 2/2/2024 |
| Michael J. McElhaugh | ▲ Buy | Grant | 123,800 | $0 | 2/1/2024 |
| J. Christopher Naftzger | ▲ Buy | Grant | 95,100 | $0 | 2/1/2024 |
| Karen Sims | ▲ Buy | Grant | 101,000 | $0 | 2/1/2024 |
| David C. Hastings | ▲ Buy | Grant | 112,500 | $0 | 2/1/2024 |
| Michael J. Sofia | ▲ Buy | Grant | 109,500 | $0 | 2/1/2024 |
| Michael J. Sofia | ▲ Buy | Grant | 82,200 | $0 | 2/1/2023 |
| Collier William H. | ▲ Buy | Grant | 216,500 | $0 | 2/1/2023 |
| Howard Elizabeth | ▲ Buy | Grant | 69,700 | $0 | 2/1/2023 |
| Michael J. McElhaugh | ▲ Buy | Grant | 83,700 | $0 | 2/1/2023 |
| David C. Hastings | ▲ Buy | Grant | 79,000 | $0 | 2/1/2023 |
| Michael J. Sofia | ▼ Sell | Open Market | 200,000 | $1.0M | 12/1/2021 |
| Roivant Sciences Ltd. | ▼ Sell | Other | 22,833,922 | — | 10/18/2021 |